RBC Capital analyst Randall Stanicky notes that the PDUFA day for Flexion's lead product, Zilretta, is on October 6, and he thinks that the product is well-positioned as an opioid alternative. He believes that the drug, a treatment for osteoarthritis of the knee, will be approved on October 6, and he thinks that the company will provide important updates during its Analyst Day on Monday, July 10 in the areas of physician views of the product and its strategy with payers. He recommends buying the stock "into and through" the Analyst Day. He keeps a $44 price target and an Outperform rating on the shares.